2018 -2019 Launch Leader Lasmiditan, Sr. Medical Fellow Migraine @ Eli Lilly and Company
2011 -2018 Senior Director, Global Medical Affairs, Alzheimer's Disease Team @ Eli Lilly and Company
2009 -2011 Neuroscience Medical Director, Emerging Markets @ Eli Lilly and Company
2007 -2009 Neuroscience Medical Director Intercontinental Region and Japan @ Eli Lilly and Company
2005 -2007 Medical Director Professional Relations @ Eli Lilly
2002 -2005 Clinical Research Physician @ Eli Lilly
1999 -2002 Associate Vice President Clinical Research Neuroscience-Canada @ Eli Lilly
1996 -1999 Depression clinic @ Center for Addiction and Mental Health
Joel Raskin Education
University of Toronto
FRCPC (Psychiatry)
1981-1986
University of Toronto - University College
MD (Medicine)
1977-1981
Joel Raskin Skills
Clinical Trials
Advisory Boards
Clinical Development
Neuroscience
Medical Affairs
Clinical Research
Commercialization
Biotechnology
Drug Development
Psychiatry
Medicine
Pharmaceutical Industry
Pharmacovigilance
Oncology
Rheumatology
Neurology
GCP
Clinical Pharmacology
Market Access
Medical Writing
Therapeutic Areas
Diabetes
Pharmacology
CRO
Endocrinology
Infectious Diseases
CTMS
Regulatory Submissions
Health Economics
ICH-GCP
Lifesciences
Osteoporosis
Translational Medicine
Clinical Study Design
Clinical Monitoring
Outcomes Research
Biomarkers
Drug Safety
Protocol
Life Sciences
Ich Gcp
Mental Health
Joel Raskin Summary
Joel Raskin, based in Toronto, ON, CA, is currently a Chief Medical Officer at Arrivo BioVentures LLC. Joel Raskin brings experience from previous roles at H2i Health Innovation Hub, Cognito Therapeutics, Inc., Joel Raskin Consulting Inc. and Alzheimer's Drug Discovery Foundation. Joel Raskin holds a 1981 - 1986 FRCPC in Psychiatry @ University of Toronto. With a robust skill set that includes Clinical Trials, Advisory Boards, Clinical Development, Neuroscience, Medical Affairs and more. Joel Raskin has 3 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Joel Raskin?
Find contact details for 700 million professionals.